



# UNITED STATES PATENT AND TRADEMARK OFFICE

ST  
UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/390,846	09/14/1999	JACOBUS JOHANNES KOK	I/95150-US/D	7646
31846	7590	06/05/2006	EXAMINER	
INTERVET INC. PATENT DEPARTMENT PO BOX 318 MILLSBORO, DE 19966-0318			MINNIFIELD, NITA M	
			ART UNIT	PAPER NUMBER
			1645	

DATE MAILED: 06/05/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	09/390,846	KOK ET AL.
	<b>Examiner</b>	<b>Art Unit</b>
	N. M. Minnifield	1645

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

1) Responsive to communication(s) filed on 23 November 2005.

2a) This action is FINAL. 2b) This action is non-final.

3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

4) Claim(s) 1,2,11,13,19 and 20 is/are pending in the application.

4a) Of the above claim(s) 13 is/are withdrawn from consideration.

5) Claim(s) \_\_\_\_\_ is/are allowed.

6) Claim(s) 1,2,11,19 and 20 is/are rejected.

7) Claim(s) \_\_\_\_\_ is/are objected to.

8) Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

9) The specification is objected to by the Examiner.

10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) All b) Some \* c) None of:

1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

1) Notice of References Cited (PTO-892)

2) Notice of Draftsperson's Patent Drawing Review (PTO-948)

3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date \_\_\_\_\_.

4) Interview Summary (PTO-413)  
Paper No(s)/Mail Date \_\_\_\_\_.

5) Notice of Informal Patent Application (PTO-152)

6) Other: \_\_\_\_\_.

**DETAILED ACTION**

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on November 23, 2005 has been entered.
2. Applicants' amendment filed November 23, 2005 is acknowledged and has been entered. Claims 3-10, 12, 14-18 and 21-26 have been canceled. Claims 1, 11, 13, 19 and 20 have been amended. Claims 1, 2, 11, 13, 19 and 20 are now pending in the present application. All rejections have been withdrawn in view of Applicants' amendment to the claims and/or comments with the exception of those discussed below.
3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
4. Newly amended claim 13 is now directed to an invention that is independent or distinct from the invention originally claimed for the following reasons: The pending claim is directed to a different process for the preparation of a coccidiosis vaccine, comprising different process steps, and different parameters, which are distinct from the original process set forth in claim 13. The pending claim would have been separated from

original claim 13 if it had been presented at the time of the restriction requirement.

Since applicant has received an action on the merits for the originally presented invention, this invention has been constructively elected by original presentation for prosecution on the merits. Accordingly, claim 13 is withdrawn from consideration as being directed to a non-elected invention. See 37 CFR 1.142(b) and MPEP § 821.03.

5. Claims 1, 2 and 19 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are vague and indefinite in the recitation of “molecular weight of about 37kD”. The claims do not define how the molecular weight was determined.

6. Claims 1, 2, 11, 19 and 20 are rejected under 35 U.S.C. 102(b) as being anticipated by Shirley, 1975, *Parasitology*, 71:369-376.

The claims are drawn to an isolated protein represented by SEQ ID NO: 2 from *Eimeria acervulina*, and vaccines comprising the protein in pharmaceutical carriers as well as a process for preparing a vaccine.

Shirley teaches lactate dehydrogenase enzyme from *E. acervulina*. The enzyme was prepared in NaCl solution (pharmaceutical carrier) and purified from sporozoites, oocysts and merozoites (pages 372, 373 and plate 1A). The protein of Shirley appears to be the same as the claimed protein. The formulation of the enzyme in NaCl meets the limitations of the claimed process. Characteristics such as immunoreactive determinants and amino

acid seq. I.D. No. 2 would be inherent in the enzyme of the prior art. The recitation of "vaccine" is being viewed as intended use of the enzyme. Applicant's use of the open-ended term "comprising" in the claims fails to exclude unrecited steps and leaves the claims open for inclusion of unspecified ingredients, even in major amounts. See In re Horvitz, 168 F 2d 522, 78 U.S.P.Q. 79 (C.C.P.A. 1948) and Ex parte Davis et al., 80 U.S.P.Q. 448 (PTO d. App. 1948). Additionally, since the Office does not have the facilities for examining and comparing applicants' protein, vaccine and process with the protein, vaccine and process of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product, vaccine and process and the product, vaccine and process of the prior art (i.e., that the protein, vaccine and process of the prior art does not possess the same material structural and functional characteristics of the claimed protein, vaccine and process). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

7. Claims 1 and 2 are rejected under 35 U.S.C. 102(b) as being anticipated by Kucera, 1989, *Folia Parasitologica* 36/4:295-299.

The claims are drawn to an isolated protein represented by SEQ ID NO: 2 from *Eimeria acervulina*.

Kucera teaches the lactate dehydrogenase enzyme from *Eimeria acervulina* and the isolation and purification of the enzyme (page 296, figure 3). The protein of Kucera appears to be the same as the claimed protein. Characteristics such as immunoreactive determinants and amino acid seq. I.D. No. 2 would be inherent in the enzyme of the prior art. The recitation of

“vaccine” is being viewed as intended use of the enzyme. Applicant's use of the open-ended term “comprising” in the claims fails to exclude unrecited steps and leaves the claims open for inclusion of unspecified ingredients, even in major amounts. See In re Horvitz, 168 F 2d 522, 78 U.S.P.Q. 79 (C.C.P.A. 1948) and Ex parte Davis et al., 80 U.S.P.Q. 448 (PTO d. App. 1948). Additionally, since the Office does not have the facilities for examining and comparing applicants' protein, vaccine and process with the protein, vaccine and process of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product, vaccine and process and the product, vaccine and process of the prior art (i.e., that the protein, vaccine and process of the prior art does not possess the same material structural and functional characteristics of the claimed protein, vaccine and process). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

8. Claims 1 and 2 are rejected under 35 U.S.C. 102(b) as being anticipated by Nakamura et al, 1991, Journal of Veterinary Medical Science, 53/6:1101-1103.

The claims are drawn to an isolated protein represented by SEQ ID NO: 2 from *Eimeria acervulina*.

Nakamura et al teach the lactate dehydrogenase enzyme from *Eimeria acervulina* and the isolation and purification of the enzyme (figure 2, c, d, f). The protein of Nakamura et al appears to be the same as the claimed protein. Characteristics such as immunoreactive determinants and amino acid seq. I.D. No. 2 would be inherent in the enzyme of the prior art. The recitation of “vaccine” is being viewed as intended use of the enzyme. Applicant's use of

the open-ended term “comprising” in the claims fails to exclude unrecited steps and leaves the claims open for inclusion of unspecified ingredients, even in major amounts. See In re Horvitz, 168 F 2d 522, 78 U.S.P.Q. 79 (C.C.P.A. 1948) and Ex parte Davis et al., 80 U.S.P.Q. 448 (PTO d. App. 1948). Additionally, since the Office does not have the facilities for examining and comparing applicants' protein, vaccine and process with the protein, vaccine and process of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product, vaccine and process and the product, vaccine and process of the prior art (i.e., that the protein, vaccine and process of the prior art does not possess the same material structural and functional characteristics of the claimed protein, vaccine and process). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

9. With regard to the prior art rejections set forth in paragraphs 4-6, these rejections have been maintained for the reasons of record. Applicant's arguments filed **November 25, 2003** have been fully considered but they are not persuasive. Applicants have asserted that the prior art (Shirley, Kucera et al, Nakamura et al) does not disclose or suggest the claimed invention of a protein expressed in vitro, comprising one or more immunoreactive and/or antigenic determinants of *Eimeria* lactate dehydrogenase (LDH), wherein said isolated protein is found intracellularly in *Eimeria*; a vaccine for the protection of poultry against Coccidiosis comprising an effective amount of an isolated protein comprising one or more immunoreactive and/or antigenic determinants of *Eimeria* lactate dehydrogenase, wherein said isolated protein is found intracellularly in *Eimeria*; and an immunogenic fragment of *Eimeria* lactate dehydrogenase (LDH), wherein said LDH is immunogenically reactive with antiserum raised against the polypeptide of SEQ ID NO:2. Applicants have asserted that the prior art, at best, discloses a native intact *Eimeria* LDH protein. Applicants have asserted that the prior art never mentions antigenic or immunogenic features nor does the prior art mention using these proteins as vaccines. Applicants completely disagree with

Art Unit: 1645

Examiner's statement that the recitation of "vaccine" is an intended use. The vaccine claims stand alone. A vaccine claim can be clearly patentable, if it is novel, even if the protein itself is anticipated. Applicants have asserted that the prior art fails to discuss a vaccine; thus, it is completely impossible for the prior art to anticipate a "vaccine" claim.

"A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, a single prior art reference." *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631, 2 U.S.P.Q.2d

1051/ 1053 (Fed. Cir. 1987). The prior art fails to disclose each element of the present invention as set forth in the claims.

With regard to Applicants' arguments, it is noted that "expressed in vitro" is viewed as a process limitation and does not negate the fact the prior art references disclose the *Eimeria* LDH. The antigenic or immunogenic features are inherent properties in the disclosed *Eimeria*. Determination of characteristics, which vary depending on the method of analysis, such as enzymatic activity, or other characteristics must be made by the same method under the same or analogous conditions to show differences that are not otherwise clearly apparent. With regard to Applicants' arguments concerning "vaccine", it is maintained that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

With regard to the 102(b) anticipation art rejections set forth above, the rejections have been maintained for the reasons of record. Applicant's arguments filed **July 29, 2004** have been fully considered but they are not persuasive. These arguments have been presented previously and addressed by the Examiner.

10. The prior art rejections have been maintained for the reasons of record. Applicant's arguments filed **February 8, 2005** have been fully considered but they are not persuasive. During an interview with Mark Milstead on November 15, 2004, Applicants' representative indicated that applicants may submit evidence that the amino acid sequence of the prior art

is not the same as the claimed SEQ ID NO: 2. the response filed February 8, 2005 does not provide any evidence that the amino acid sequence of the prior art is not the same as the claimed SEQ ID NO: 2. Applicants have asserted that the prior art fails to disclose or suggest a protein expressed *in vitro* comprising an isolated protein found intracellularly in *Eimeria* and is represented by the amino acid sequence shown in SEQ ID NO: 2 and a vaccine for the protection of poultry against Coccidiosis comprising an effective amount of an isolated protein as described above. Applicants have asserted that at best the references disclose a native intact *Eimeria* LDH protein and that none of the references mention using these proteins as vaccines. Applicants have asserted that a vaccine claims can be clearly patentable, it is novel, even if the protein itself is anticipated and that the references fail to anticipate a “vaccine”.

However, as previously stated the recitation of “expressed *in vitro*” is viewed as a process limitation and does not negate the fact the prior art references disclose the *Eimeria* LDH, the specifically claimed species of *Eimeria acervulina* is also disclosed. Characteristics such as the amino acid SEQ ID NO: 2 would be inherent in the enzyme of the prior art. Determination of characteristics, which vary depending on the method of analysis, such as enzymatic activity, amino acid sequence or other characteristics must be made by the same method under the same or analogous conditions to show differences that are not otherwise clearly apparent. With regard to Applicants’ arguments concerning “vaccine”, it is maintained that a recitation of the intended use of the claimed invention must result in a structural difference between the claimed invention and the prior art in order to patentably distinguish the claimed invention from the prior art. If the prior art structure is capable of performing the intended use, then it meets the claim. In a claim drawn to a process of making, the intended use must result in a manipulative difference as compared to the prior art. See *In re Casey*, 152 USPQ 235 (CCPA 1967) and *In re Otto*, 136 USPQ 458, 459 (CCPA 1963).

Applicants’ have amended the claims to delete the recitation of “*Eimeria* lactate dehydrogenase (LDH)”. However, the specification teaches that “...this protein is found intracellularly in *Eimeria* and it appears to contain high sequence homology with known heterologous lactate dehydrogenases (LDH). Thus, the invention provides a protein having one or more immunoreactive and/or antigenic determinants of *Eimeria* lactate dehydrogenase, which has a monomeric molecular weight of about 37 kD. More specifically the lactate dehydrogenase is derived from *Eimeria*

*acervulina.*" (specification p. 6) "More particularly, this invention provides proteins possessing LDH activity, or immunogenically active parts thereof, which have the amino acid sequence shown in SEQ ID NO. 2 and their biologically functional equivalents or variants." (specification p. 7) Even though Applicants have deleted a specific functional characteristic of the protein (lactate dehydrogenase activity), the specification teaches that claimed protein represented by the amino acid sequence shown in SEQ ID NO: 2 has LDH activity. Therefore, the prior art discloses the claimed invention.

With regard to Applicants' arguments regarding inherency, MPEP 2112.01 states that "[W]here the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case of either anticipation or obviousness has been established. *In re Best*, 562 F.2d 1252, 1255, 195 USPQ 430, 433 (CCPA 1977). "When the PTO shows a sound basis for believing that the products of the applicant and the prior art are the same, the applicant has the burden of showing that they are not." *In re Spada*, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658 (Fed. Cir. 1990). Therefore, the prima facie case can be rebutted by evidence showing that the prior art products do not necessarily possess the characteristics of the claimed product. *In re Best*, 562 F.2d at 1255, 195 USPQ at 433.

With regard to Applicants' assertion that a vaccine claim can be clearly patentable, it is novel, even if the protein itself is anticipated and that the references fail to anticipate a vaccine". It is noted that the MPEP 2112 states that "[T]he discovery of a previously unappreciated property of a prior art composition, or of a scientific explanation for the prior art's functioning, does not render the old composition patentably new to the discoverer." *Atlas Powder Co. v. Ireco Inc.*, 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1947 (Fed. Cir. 1999). Thus the claiming of a new use, new function or unknown property, which is inherently present in the prior art, does not necessarily make the claim patentable. *In re Best*, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977).

Since the Office does not have the facilities for examining and comparing applicants' protein and vaccine with the protein and vaccine of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and vaccine and the product and vaccine of the prior art (i.e., that the protein and vaccine of the prior art does not possess the same material structural and functional characteristics of the

claimed protein and vaccine). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

11. The prior art rejections set forth in paragraphs 6-8 of this office action have been maintained for the reasons of record. Applicant's arguments filed November 23, 2005 have been fully considered but they are not persuasive. Applicants' arguments have been presented previously and addressed by the Examiner, see paragraphs 9 and 10 of this office action. With regard to the new limitation of a specific molecular weight, it is noted that the claims do not set forth how the molecular weight of the protein was determined. Since the method of molecular weight determination has not been set forth, it would appear that the prior art discloses the same polypeptide. The prior art discloses that the protein is a LDH from *Eimeria acervulina*, see for example Nakamura et al, and the specification teaches that the LDH has a molecular weight of 37 kD. The mere discovery of an amino acid sequence, molecular weight or other characterizing features of a protein, which protein is taught by the prior art, imparts neither novelty nor unobviousness to the protein. Further, given that the protein(s) was known in the prior art, one of ordinary skill in the art would have been motivated to identify the amino acid sequence, molecular weight and whether or not the protein is glycosylated since proteins are routinely characterized in this manner. Therefore, the proteins of the reference appear to be consistent with those claimed with the various identifying characteristics inherent in them. Since the Office does not have the facilities for examining and comparing applicants' protein with the protein of the prior art, the burden is on applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the protein of the prior art does not possess the same

material structural and functional characteristics of the claimed protein). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

12. Acknowledgment is made of applicant's claim for foreign priority based on an application filed in EPO 95201801.8 on July 3, 1995. It is noted, however, that applicant has not filed a certified copy of the EPO 95201801.8 application as required by 35 U.S.C. 119(b).


Upon further review of the application file, it is noted that Applicants have not perfected the priority documents and therefore their priority date. The Examiner acknowledges that Applicants were previously informed that the priority documents found in Application 08/676882 were sufficient to meet the priority requirements. However, this information was incorrect; 08/676882 is not the parent of this application. There is no relationship (parent, divisional, continuation) between these two applications.

13. No claims are allowed.

14. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette R.F. Smith can be reached on 571-272-0864. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.



N. M. Minnfield  
Primary Examiner  
Art Unit 1645

NMM  
May 26, 2006